The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step [TheStreet.com]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: TheStreet.com
USANewsGroup.com VANCOUVER, BC March 31, 2026 /PRNewswire/ -- The FDA has approved more than 40 cell and gene therapy products. The regenerative medicine market is projected to reach $578 billion by 2033 Cell therapy alone surpassed $8.2 billion this year . And yet the central challenge of the entire sector remains unresolved: how do you manufacture living therapeutics at scale, consistently, and affordably? Every cell therapy company confronts the same bottleneck. You can discover a transformative biological mechanism in a lab. You can prove it works in a trial. But the moment you need to produce it reliably for thousands or millions of patients, you run into the manufacturing wall. The cells degrade. The immune system rejects them. The supply chain breaks. The companies that solve manufacturing are the ones that will capture the value in this market. That manufacturing challenge is driving some of the most important milestones in the sector right now. Prime Medicine (NASDAQ:
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge? [Yahoo! Finance]Yahoo! Finance
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire